title: Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia.
abstract: Persons with Fanconi anemia (FA) are at risk for human papillomavirus (HPV)-associated cancers; however, their natural HPV exposure and infection rates are unknown as is the adequacy with which they mount antibodies to HPV vaccination. This study aimed to determine, in 62 persons with FA, the seroprevalence of skin and mucosal HPV types, the seroprevalence in individuals self-reporting a history of HPV vaccination, and the factors associated with HPV seropositivity. A bead Luminex assay was used to determine seropositivity for HPV1, -2, and -4 (low-risk skin), -6 and -11 (low-risk mucosal, included in one HPV vaccine), -16 and -18 (high-risk mucosal, included in both HPV vaccines), and -52 and -58 (high-risk mucosal). Health- and behavior-related questionnaires were completed. Type-specific seroprevalence estimates and participant characteristics associated with seroprevalence were calculated; 48% reported HPV vaccination. Type-specific seropositivity in unvaccinated persons ranged from 7 to 21% for skin HPV types and 7 to 38% for mucosal HPV types. Among the unvaccinated participants, adults versus children demonstrated increased HPV1, -6, -16, and -58 seroprevalence of 45% versus 6%, 64% versus 22%, 64% versus 17%, and 36% versus 0%, respectively (all P < 0.05). The vaccinated participants versus the nonvaccinated participants demonstrated increased seroprevalence of HPV6, -11, -16, and -18 of 92% versus 38%, 92% versus 24%, 96% versus 34%, and 75% versus 7%, respectively (all P < 0.0001). Our data demonstrate that the unvaccinated participants had serologic evidence of prior skin and mucosal HPV infections and that seroprevalence increased among adults; in self-reported vaccinees, seroprevalence of HPV vaccine types was 75 to 96%.
authors: Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA Department of Pediatrics, University of Washington, Seattle, Washington, USA rkatzen@uw.edu.
authors: Rachel A
authors: RA
authors: Katzenellenbogen
authors: Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Joseph J
authors: JJ
authors: Carter
authors: Department of Global Health, University of Washington, Seattle, Washington, USA.
authors: Joshua E
authors: JE
authors: Stern
authors: Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
authors: Melinda S
authors: MS
authors: Butsch Kovacic
authors: Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
authors: Parinda A
authors: PA
authors: Mehta
authors: Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
authors: Sharon L
authors: SL
authors: Sauter
authors: Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Denise A
authors: DA
authors: Galloway
authors: Department of Epidemiology, University of Washington, Seattle, Washington, USA.
authors: Rachel L
authors: RL
authors: Winer
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005199:Fanconi Anemia / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000276:immunology; D016036:Seroepidemiologic Studies; D065288:Serogroup; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral
references: J Natl Cancer Inst. 2009 Nov 4;101(21):1510-22
references: 19776382
references: Lancet Infect Dis. 2011 Jan;11(1):39-44
references: 21067976
references: J Immunol Methods. 2001 Jul 1;253(1-2):153-62
references: 11384677
references: Gynecol Oncol. 2002 Feb;84(2):263-70
references: 11812085
references: Blood. 2003 Feb 1;101(3):822-6
references: 12393424
references: N Engl J Med. 2003 Feb 6;348(6):518-27
references: 12571259
references: J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21
references: 14625263
references: Cancer. 2004 Jul 15;101(2):270-80
references: 15241823
references: Virology. 1994 Mar;199(2):284-91
references: 7510082
references: J Natl Cancer Inst. 1997 Oct 15;89(20):1516-23
references: 9337348
references: Lancet. 2004 Nov 13-19;364(9447):1757-65
references: 15541448
references: Clin Chem. 2005 Oct;51(10):1845-53
references: 16099939
references: Pediatrics. 2006 Nov;118(5):2135-45
references: 17079588
references: JAMA. 2007 Feb 28;297(8):813-9
references: 17327523
references: J Virol. 2007 Dec;81(23):13265-70
references: 17898070
references: J Clin Oncol. 2008 Feb 1;26(4):612-9
references: 18235120
references: Haematologica. 2008 Apr;93(4):511-7
references: 18322251
references: PLoS Pathog. 2008 Jun;4(6):e1000091
references: 18566657
references: Cancer. 2008 Dec 15;113(12):3315-22
references: 18831513
references: Oncogene. 2009 Feb 5;28(5):674-85
references: 19015634
references: J Biomed Inform. 2009 Apr;42(2):377-81
references: 18929686
references: J Infect Dis. 2009 Oct 1;200(7):1059-67
references: 19719390
references: Pediatrics. 2009 Dec;124(6):1505-12
references: 19933728
references: J Natl Cancer Inst. 2010 Mar 3;102(5):325-39
references: 20139221
references: Virology. 2010 May 25;401(1):70-9
references: 20206957
references: APMIS. 2010 Jun;118(6-7):510-9
references: 20553531
references: Br J Haematol. 2010 Jul;150(2):179-88
references: 20507306
references: BMJ. 2010;341:c3493
references: 20647284
references: N Engl J Med. 2011 Feb 3;364(5):401-11
references: 21288094
references: J Infect Dis. 2011 Jul 15;204(2):209-16
references: 21673030
references: Lancet. 2011 Jun 18;377(9783):2085-92
references: 21684381
references: N Engl J Med. 2011 Oct 27;365(17):1576-85
references: 22029979
references: J Clin Oncol. 2011 Nov 10;29(32):4294-301
references: 21969503
references: J Pathol. 2012 Jan;226(2):326-37
references: 21956823
references: J Adolesc Health. 2012 Jan;50(1):103-5
references: 22188843
references: Lancet Oncol. 2012 Jan;13(1):89-99
references: 22075171
references: Int J Gynecol Cancer. 2012 Feb;22(2):303-10
references: 22228426
references: IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
references: 23189750
references: Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
references: 23199964
references: Vaccine. 2012 Nov 20;30 Suppl 5:F34-54
references: 23199965
references: Sex Transm Dis. 2013 Feb;40(2):130-5
references: 23324976
references: J Infect Dis. 2013 Aug 1;208(3):385-93
references: 23785124
references: PLoS One. 2013;8(9):e74797
references: 24058629
references: Vaccine. 2013 Oct 9;31(43):4935-9
references: 23994822
references: J Adolesc Health. 2013 Nov;53(5):674-6
references: 24035133
references: Vaccine. 2014 Feb 26;32(10):1169-73
references: 24295807
references: J Natl Cancer Inst. 2014 Mar;106(3):djt460
references: 24552678
references: BMC Infect Dis. 2014;14:361
references: 24990706
references: Sex Transm Infect. 2014 Sep;90(6):505-8
references: 24748563
references: J Acquir Immune Defic Syndr. 2010 Oct;55(2):197-204
references: 20574412
references: J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62
references: 20944077
references: Cancer Res. 2010 Dec 1;70(23):9959-68
references: 20935219
references: J Infect Dis. 2011 Jan 1;203(1):58-65
references: 21148497
references: J Infect Dis. 2000 Jun;181(6):1911-9
references: 10837170